Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Tenax Therapeutics, Inc.NASDAQ: TENX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 21.6% from a year ago
Other current assets stood at $107K at the end of Q1 FY2026, up 21.6% from a year earlier and down 89.5% from the prior quarter. Over 3 fiscal years it compounded at +43.4% a year.
Context
- Other current assets amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +21.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.02M USD
- Year-over-year change
- +1492.2%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.02M | +1492.2% |
| FY2024 | 2024-12-31 | 64K | -74.6% |
| FY2023 | 2023-12-31 | 251.58K | -27.3% |
| FY2022 | 2022-12-31 | 345.86K | +71605797101449376.0% |
| FY2021 | 2021-12-31 | (0) | — |
Other Current Assets vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 other current assets of $107K is the lowest of the 7 companies compared; the peer median is $2.91M.
- Its year-over-year change of +21.6% is the 5th highest of 7, against a peer median of +284.2%.
- Other current assets amounts to 0.1% of total assets for TENX, versus a peer median of 3.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.47B | +1490234.9% | -41.9% | 4.7% | |
| Mar 2026 | $6.45M | +6836.6% | +259.0% | 10.1% | |
| Jun 2026 | $3.46M | -3.7% | — | 1.5% | |
| Mar 2026 | $2.37M | +34.0% | +3.0% | 6.1% | |
| Mar 2026 | $1.9M | +534.3% | -26.1% | 2.2% | |
| Mar 2026 | $1.77M | -16.2% | +15.4% | 1.3% | |
| Mar 2026 | $107K | +21.6% | +43.4% | 0.1% | |
| Peer median (excluding TENX) | $2.91M | +284.2% | +3.0% | 3.4% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.